‘Michael’ Won’t Stop ‘Til It Gets Enough: Michael Jackson Biopic Eyes $150M WW Debut – Preview

Lionsgate’s Michael Jackson biopic is tracking a strong $65M-$70M domestic opening and roughly $150M global debut, with overseas expected at $75M-$80M across 82 markets. The film’s release was delayed by reshoots tied to legal clearance issues, but presales are described as strong and it is positioned for a record start for a music biopic. Despite a weak 33% Rotten Tomatoes score, audience demand and international interest—especially in markets like Germany, Brazil, Mexico, and Japan—remain the key drivers.

Analysis

IMAX is the cleaner expression than the underlying studio exposure here. A tentpole with this kind of premium-format mix can create an unusually asymmetric revenue step-up for IMAX because the incremental box office share from large-format screens is high-margin and front-loaded into the first 2-3 weekends; if the opening lands near the high end, the market will likely re-rate IMAX’s 1H mix before results even show up. The second-order effect is that a strong run here also validates premium large-format capacity at a time when exhibitors need eventized content to defend pricing power.

The key risk is that the market may already be discounting a “perfect nostalgia trade” and underappreciating how fragile that is to audience dispersion after weekend one. For the studio side, this is less a pure box-office story than a risk-management story: foreign pre-sales mitigate downside, but the real upside optionality is in Japan and repeatability across older-skewing overseas markets over the next 4-8 weeks. If those territories underperform, the multiple expansion thesis for music-biopic-driven slate momentum fades quickly.

For SONY, this is only an indirect read-through via the broader premium-content ecosystem, not a direct earnings catalyst. Still, a strong result would support the valuation case for event-driven theatrical monetization across studios and exhibitors, which matters because the market remains skeptical that large-budget non-franchise IP can reliably clear its cost of capital. The contrarian miss is on the downside: a modest domestic opening would be enough to compress sentiment materially because expectations have moved from “good” to “record-setting,” and that setup usually creates a sharp post-open de-rating even if the film eventually grosses well.

Key Decisions for Investors

• Long IMAX into the opening weekend, with a 1-3 week horizon; best risk/reward is to scale in on any pre-weekend softness and take partial profits on an opening print above the current high tracking band, since the stock should react fastest to premium-format overperformance.
• Pair trade: long IMAX / short a broad exhibitor basket proxy over 2-6 weeks; the thesis is that premium-format mix and eventization matter more than aggregate box office, and IMAX captures that lever better than legacy theater operators.
• For SONY, avoid chasing the move; use it only as a sentiment read-through. If box office beats and premium-screen utilization is strong, consider a modest tactical long via calls into the next slate/event-film window, but keep size small because the direct earnings linkage is weak.
• Buy short-dated IMAX upside calls only if you can tolerate event risk; structure with defined downside because a miss against elevated expectations can unwind quickly in 1-2 sessions.
• If opening weekend tracks below the upper band, fade the enthusiasm rather than the film itself: the trade would be to reduce IMAX exposure on any post-release spike, since the market will likely overshoot on ‘record launch’ headlines before weekend-two retention data confirms the thesis.